233 related articles for article (PubMed ID: 31393257)
1. Synthesis and Anticancer Activity of Benzimidazole/Benzoxazole Substituted Triazolotriazines in Hepatocellular Carcinoma.
Dadashpour S; Küçükkılınç TT; Ercan A; Hosseinimehr SJ; Naderi N; Irannejad H
Anticancer Agents Med Chem; 2019; 19(17):2120-2129. PubMed ID: 31393257
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase.
Yuan X; Yang Q; Liu T; Li K; Liu Y; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
Eur J Med Chem; 2019 Oct; 179():147-165. PubMed ID: 31252306
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of some novel benzothiazole/benzoxazole and/or benzimidazole derivatives incorporating a pyrazole scaffold as antiproliferative agents.
Abdelgawad MA; Bakr RB; Omar HA
Bioorg Chem; 2017 Oct; 74():82-90. PubMed ID: 28772160
[TBL] [Abstract][Full Text] [Related]
4. 4-{3-[(Pyridin-4-ylmethyl)amino]-[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}phenol: An improved anticancer agent in hepatocellular carcinoma and a selective MDR1/MRP modulator.
Khatir ZZ; Di Sotto A; Percaccio E; Tuylu Kucukkilinc T; Ercan A; Chippindale AM; Valipour M; Irannejad H
Arch Pharm (Weinheim); 2024 Jun; 357(6):e2300704. PubMed ID: 38442326
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
7. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking.
Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA
Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
Zhai S; Zhang H; Chen R; Wu J; Ai D; Tao S; Cai Y; Zhang JQ; Wang L
Eur J Med Chem; 2021 Dec; 225():113824. PubMed ID: 34509167
[TBL] [Abstract][Full Text] [Related]
10. Thieno[2,3-d]pyrimidin-4(3H)-one Derivatives of Benzimidazole as Potential Anti- Breast Cancer (MDA-MB-231, MCF-7) Agents.
Dimov S; Mavrova AT; Yancheva D; Nikolova B; Tsoneva I
Anticancer Agents Med Chem; 2021; 21(11):1441-1450. PubMed ID: 32698751
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative activity, enzymatic inhibition and apoptosis-promoting effects of benzoxazole-based hybrids on human breast cancer cells.
Omar AME; AboulWafa OM; Amr ME; El-Shoukrofy MS
Bioorg Chem; 2021 Apr; 109():104752. PubMed ID: 33657444
[TBL] [Abstract][Full Text] [Related]
12. In-vitro Anti-cancer assay and apoptotic cell pathway of newly synthesized benzoxazole-N-heterocyclic hybrids as potent tyrosine kinase inhibitors.
Desai S; Desai V; Shingade S
Bioorg Chem; 2020 Jan; 94():103382. PubMed ID: 31662214
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel 1,2,4-triazolo-1,2,4-triazines with thiomethylpyridine hinge binders as potent c-Met kinase inhibitors.
Dadashpour S; Kϋçϋkkılınç TT; Ayazgök B; Hosseinimehr SJ; Chippindale AM; Foroumadi A; Irannejad H
Future Med Chem; 2019 May; 11(10):1119-1136. PubMed ID: 31280674
[No Abstract] [Full Text] [Related]
14. Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
El-Helby AA; Sakr H; Eissa IH; Al-Karmalawy AA; El-Adl K
Arch Pharm (Weinheim); 2019 Dec; 352(12):e1900178. PubMed ID: 31596514
[TBL] [Abstract][Full Text] [Related]
15. New pyrimidine-benzoxazole/benzimidazole hybrids: Synthesis, antioxidant, cytotoxic activity, in vitro cyclooxygenase and phospholipase A2-V inhibition.
Abdelgawad MA; Bakr RB; Ahmad W; Al-Sanea MM; Elshemy HAH
Bioorg Chem; 2019 Nov; 92():103218. PubMed ID: 31536956
[TBL] [Abstract][Full Text] [Related]
16. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met.
Ibrahim HA; Awadallah FM; Refaat HM; Amin KM
Bioorg Chem; 2018 Apr; 77():457-470. PubMed ID: 29453077
[No Abstract] [Full Text] [Related]
18. New steroidal oxazolines, benzoxazoles and benzimidazoles related to abiraterone and galeterone.
Latysheva AS; Zolottsev VA; Veselovsky AV; Scherbakov KA; Morozevich GE; Pokrovsky VS; Novikov RA; Timofeev VP; Tkachev YV; Misharin AY
Steroids; 2020 Jan; 153():108534. PubMed ID: 31678134
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of Some Benzimidazole-derived Molecules and their Effects on PARP-1 Activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 Breast Cancer Cell Viability.
Gurkan-Alp AS; Alp M; Karabay AZ; Koc A; Buyukbingol E
Anticancer Agents Med Chem; 2020; 20(14):1728-1738. PubMed ID: 32357823
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors.
Akhtar MJ; Khan AA; Ali Z; Dewangan RP; Rafi M; Hassan MQ; Akhtar MS; Siddiqui AA; Partap S; Pasha S; Yar MS
Bioorg Chem; 2018 Aug; 78():158-169. PubMed ID: 29571113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
